Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Research Article

Ferulic Acid Dose Effect on Pharmacokinetics of Glimepiride and its Metabolite Hydroxy Glimepiride in Rats

Author(s): Yuxian Lin, Faxin Sun, Jinlai Liu, Qinghua Weng, Lijun Jin, Linguo Chen, Yiwei Huang and Hui Xu*

Volume 18, Issue 3, 2022

Published on: 04 June, 2021

Page: [316 - 324] Pages: 9

DOI: 10.2174/1573412917666210604162556

Abstract

Background: To mitigate diabetes and its complications in cardiovascular diseases, the antidiabetic agent Glimepiride (GLM) is usually administered with Ferulic Acid (FA) concomitantly in clinical settings. However, both drugs are prone to be metabolized partly by CYP2C9; thus, they have the potential drug-drug interaction affecting safety and efficacy.

Objective: This study aimed to evaluate the Pharmacokinetic (PK) effects of ferulic acid on glimepiride and its metabolite hydroxy glimepiride (OH-GLM) in plasma by using the HPLCMS/ MS method.

Methods: Healthy male Sprague Dawley (SD) rats were randomly divided into three groups and received intragastric administration of 0.5% sodium Carboxymethyl Cellulose (CMC), low-dose of FA (20 mg•kg-1 ), and high-dose of FA (40 mg•kg-1) for 8 days, respectively. Rats were given 0.5% sodium CMC or FA on the last day and then uniformly given 1.0 mg•kg-1 glimepiride by gavage. Blood samples were obtained from retro-orbital plexus at the time points of 0.167, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after administration. Plasma samples were analyzed for GLM and its metabolite OH-GLM on an HPLC-MS/MS system.

Results: No statistically significant difference was found in the effect of low-dose of FA on the pharmacokinetics of GLM. However, high-dose of FA significantly decreased Cmax of GLM by 30.05% and CLz/F of OH-GLM by 47.45% and increased Tmax and t1/2z of GLM by 95.87% and 140.00%, respectively.

Conclusion: Low-dose of FA did not alter GLM metabolism, while high-dose treatment of FA apparently caused pharmacokinetics interaction with GLM in rats.

Keywords: Ferulic acid, glimepiride, hydroxy glimepiride, pharmacokinetics, HPLC-MS/MS, diabetes mellitus.

« Previous Next »
Graphical Abstract

[1]
Dake AW, Sora ND. Diabetic dyslipidemia review: An update on current concepts and management guidelines of diabetic dyslipidemia. Am J Med Sci 2016; 351(4): 361-5.
[http://dx.doi.org/10.1016/j.amjms.2016.01.020] [PMID: 27079341]
[2]
Aragno M, Parola S, Tamagno E, et al. Oxidative derangement in rat synaptosomes induced by hyperglycaemia: restorative effect of dehydroepiandrosterone treatment. Biochem Pharmacol 2000; 60(3): 389-95.
[http://dx.doi.org/10.1016/S0006-2952(00)00327-0] [PMID: 10856434]
[3]
Bumrungpert A, Lilitchan S, Tuntipopipat S, Tirawanchai N, Komindr S. Ferulic acid supplementation improves lipid profiles, oxidative stress, and inflammatory status in hyperlipidemic subjects: a randomized, double-blind, placebo-controlled clinical trial. Nutrients 2018; 10(6): 713.
[http://dx.doi.org/10.3390/nu10060713] [PMID: 29865227]
[4]
Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212(2): 167-78.
[http://dx.doi.org/10.1016/j.taap.2006.01.003] [PMID: 16490224]
[5]
Ou S, Kwok KC. Ferulic acid: pharmaceutical functions, preparation and applications in food. J Sci Food Agric 2004; 84: 1261-9.
[http://dx.doi.org/10.1002/jsfa.1873]
[6]
Zhang D, Bi Z, Li Y, et al. Sodium ferulate modified gene expression profile of oxidized low-density lipoprotein-stimulated human umbilical vein endothelial cells. J Cardiovasc Pharmacol Ther 2009; 14(4): 302-13.
[http://dx.doi.org/10.1177/1074248409347986] [PMID: 19837969]
[7]
Wang BH, Ou-Yang JP. Pharmacological actions of sodium ferulate in cardiovascular system. Cardiovasc Drug Rev 2005; 23(2): 161-72.
[http://dx.doi.org/10.1111/j.1527-3466.2005.tb00163.x] [PMID: 16007232]
[8]
Song Y, Wen L, Sun J, et al. Cytoprotective mechanism of ferulic acid against high glucose-induced oxidative stress in cardiomyocytes and hepatocytes. Food Nutr Res 2016; 60: 30323.
[http://dx.doi.org/10.3402/fnr.v60.30323] [PMID: 26869273]
[9]
Zavoshy R, Noroozi M, Jahanihashemi H. Effect of low calorie diet with rice bran oil on cardiovascular risk factors in hyperlipidemic patients. J Res Med Sci 2012; 17(7): 626-31.
[PMID: 23798921]
[10]
Mancuso C, Santangelo R. Ferulic acid: pharmacological and toxicological aspects. Food Chem Toxicol 2014; 65: 185-95.
[http://dx.doi.org/10.1016/j.fct.2013.12.024] [PMID: 24373826]
[11]
Zhuang XM, Chen L, Tan Y, et al. Identification of human cytochrome P450 and UGT enzymes involved in the metabolism of ferulic acid, a major bioactive component in traditional Chinese medicines. Chin J Nat Med 2017; 15(9): 695-702.
[http://dx.doi.org/10.1016/S1875-5364(17)30099-7] [PMID: 28991531]
[12]
Rosskamp R, Wernicke-Panten K, Draeger E. Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 1996; 31(Suppl.): S33-42.
[http://dx.doi.org/10.1016/0168-8227(96)01228-4] [PMID: 8864639]
[13]
Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003; 25(3): 799-816.
[http://dx.doi.org/10.1016/S0149-2918(03)80109-1] [PMID: 12852703]
[14]
Fu JF, Ren QY, Zhang NY, et al. Inhibition potential of glimepiride (gli) towards important UDP-glucuronosyltransferase (UGT) isoforms in human liver. Pharmazie 2012; 67(8): 715-7.
[PMID: 22957438]
[15]
Yan N, Tang Z, Xu Y, Li X, Wang Q. Pharmacokinetic Study of Ferulic Acid Following Transdermal or Intragastric Administration in Rats. AAPS PharmSciTech 2020; 21(5): 169.
[http://dx.doi.org/10.1208/s12249-020-01709-w] [PMID: 32514600]
[16]
Lee J, Chae SW, Ma L, Lim SY, Alnajjar S. Park, Choo, H.Y.; Lee, H.J.; Rhie, S.J. Pharmacokinetic alteration of paclitaxel by ferulic acid derivative. Pharmaceutics 2019; 11: 593.
[http://dx.doi.org/10.3390/pharmaceutics11110593]
[17]
Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 2003; 43(1): 84-91.
[http://dx.doi.org/10.1177/0091270002239710] [PMID: 12520632]
[18]
Iwakawa S, Miyashita K, Hashimoto Y, Kuroda T. Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3. Biol Pharm Bull 2006; 29(9): 1983-5.
[http://dx.doi.org/10.1248/bpb.29.1983] [PMID: 16946524]
[19]
Park JW, Kim KA, Choi YJ, Yoon SH, Park JY. Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. J Clin Pharm Ther 2019; 44(5): 720-5.
[http://dx.doi.org/10.1111/jcpt.12848] [PMID: 31094010]
[20]
Kim CO, Oh ES, Kim H, Park MS. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Drug Des Devel Ther 2017; 11: 503-12.
[http://dx.doi.org/10.2147/DDDT.S129586] [PMID: 28260863]
[21]
Surendran S, Paul D, Sushmita R, et al. A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1046: 218-25.
[http://dx.doi.org/10.1016/j.jchromb.2017.01.009] [PMID: 28159531]
[22]
Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Miners JO. The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos 2007; 35(3): 363-70.
[http://dx.doi.org/10.1124/dmd.106.013052] [PMID: 17151189]
[23]
Muthusamy G, Balupillai A, Ramasamy K, et al. Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines. Eur J Pharmacol 2016; 786: 194-203.
[http://dx.doi.org/10.1016/j.ejphar.2016.05.023] [PMID: 27262378]
[24]
Ghosh S, Chowdhury S, Sarkar P, Sil PC. Ameliorative role of ferulic acid against diabetes associated oxidative stress induced spleen damage. Food Chem Toxicol 2018; 118: 272-86.
[http://dx.doi.org/10.1016/j.fct.2018.05.029] [PMID: 29758315]
[25]
Chen M, LeDuc B, Kerr S, Howe D, Williams DA. Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Drug Metab Dispos 2010; 38(3): 368-75.
[http://dx.doi.org/10.1124/dmd.109.029900] [PMID: 20008037]
[26]
Gaganis P, Miners JO, Brennan JS, Thomas A, Knights KM. Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther 2007; 323(2): 422-30.
[http://dx.doi.org/10.1124/jpet.107.128603] [PMID: 17698974]

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy